Human Papillomavirus ( Hpv )

What is the Human Papillomavirus? Commonly known as HPV, it is an infection that spreads through sexual contact. There are over one hundred different types of HPV; several types cause genital warts, while other high risk strands can lead to cancer of the cervix, anus, vagina, and penis. Because HPV is often asymptomatic, many people are unaware of their infection status, and thus, their potential for transmitting the virus to a sexual partner. The significance of the Human Papillomavirus is that fifty percent of Americans who are sexually active will contract it within their lives, and at any given point there are twenty million Americans already infected with it (“By the numbers: HPV Vaccine”).

HPV is so common in the United States that nearly all men and women will contract the virus at some point during life (Center for Disease Control and Prevention [CDC], 2017). In the United States, in 2008, it is reported that 3.2 million, or one in four adolescent women, ages 14 to 19 have had or have an STD (Kostas-Polston et al., 2012). The rate of HPV cases has only increased since 2008. The prevalence of a genital infection with any HPV type was 42.5% among United States during 2013–2014 (CDC, 2017). The incidence of HPV in the United States is about 14 million people each year.

The HPV virus has gone unseen by many until the recent controversy over the vaccine. However, this virus is thought to be one of the world’s most wide spread STD’s. “According to the Centers for Disease Control and Prevention (CDC), about 6.2 million women and men are newly infected every year” with HPV. HPV has over 100 strains, with more than thirty that are sexually transmitted. Some of these strains are known to cause cervix, vulva, vagina, anus, or penis cancers and others can cause genital warts. “Studies have found the vaccine to be almost 100% effective in preventing diseases caused by the four HPV types covered by the vaccine—including precancers of the cervix, vulva and vagina, and genital warts” (“HPV Questions and

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

The authors appreciated the fact that Canada recently approved the use of the vaccine for males, which should decrease cervical, penile, and anal cancer rates and help in cost-savings. Unfortunately, the awareness of the new HPV vaccines remains low despite its efficacy and a small number of adverse

Almost all cervical carcinomas are caused by Human papillomavirus (HPV). Cervical cancer can be a life-threating disease. However, over recent years the occurrence of cervical cancer has declined as well as the chance of dying from it. A huge contributing factor to this decline is the importance of a regular pap smear. A pap smear can find cervical pre-cancer before it turns into cancer. Recently, a vaccine for HPV, has been on the market, which provides close to a 100% protection against pre-cancer and general warts. HPV and cervical cancer are two disease that are closely related. However, each disease effects not only similar populations, but also different populations, as well as having its own signs and symptoms, detection procedures,

Human Papilloma Virus, more commonly known as HPV, is a sexually transmitted virus. It is spread from skin-to-skin contact with an infected person, typically during sexual encounters. It is the most common sexually transmitted disease in the United States. According to the Immunize Action Coalition, “most sexually active American men and woman will contract at least one type of HPV virus during their lifetime” (A Parent 's Guide to Preteen, 2013, p. 1). To put the numbers in perspective, it infects an estimated seventy-nine million Americans today with approximately fourteen million more people being affected additionally each year (Human

HPV is the number one sexually transmitted infection (STI) in the United States, and anyone who is sexually active is at risk of contracting the virus. HPV is transmitted through intimate skin-to-skin contact with someone who has the virus, and it is so common that most all sexually active men and women encounter a strain without ever knowing they’re infected (CDC). There are many strains of the HPV virus, some of which don’t cause cervical cancer. To help understand and classify the types of HPV, the terms low-risk and high-risk HPV are used. Some

The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are over 100 types of HPV, but only 40 types affect the genital area and can cause genital warts and cervical cancer in women (“Human Papillomavirus (HPV) Vaccine”). In 2011 in the United States, 12,109 women were diagnosed with cervical cancer. Of those, 4,092 women died (“Cervical Cancer Statistics”). HPV is not only contracted from sexual intercourse, but also from skin to skin contact, including oral sex. The STI affects males and females involved in both homosexual and heterosexual sexual activities. Over 70 percent of sexually active individuals contract and carry HPV before the age of 80. In order to combat HPV two different brands of HPV vaccination – Gardasil and Cervarix – were created. Both include a vaccination plan of three shots over the course of six months. Gardasil was created by Merck & Co., and was licensed by the FDA in June 2006. The vaccine protects against HPV types 16 and 18, which lead to cervical cancer, as well as types 6 and 11, which cause 90% of genital warts. The FDA later approved Cervarix, created by GlaxoSmithKline, in 2009, which only protects against HPV types 16 and 18 (“Human Papillomavirus (HPV) Vaccine”). Originally, Gardasil was only approved for females, but three years after the release, the vaccine was approved

(Attention Getter) The Center for Disease Control reports that 100% of sexually active men and women contract genital HPV

The HPV vaccine should be required on the grounds that it will reduce sexually transmitted infections in the United States. The human papillomavirus is spread and contracted through sexual intercourse. Around twenty million people have the human papillomavirus in the United States (Creel). An abundance of people do not realize that they have been infected by the human papillomavirus since it has no symptoms, thus making the virus dangerous. If a person has the human papilloma virus and does not acquire treatment, it can lead to cancer or genital warts. Women might learn if they have contracted the human papilloma virus if they have a Pap smear test done. Unfortunately, men are not able to know if they have the virus unless they develop genital warts or cancer. Research shows that the HPV vaccine, "produces a strong immune response when tested" (Creel). If a person decides to receive the vaccine when required and is ever exposed to the virus the chances of contracting the virus are extremely low. As of today, studies show that both HPV vaccines can reduce the risk of contracting cancer and genital warts

Human Papillomavirus(HPV) is the most common sexually transmitted infection in the United States, according to Centers for Disease Control and Prevention(CDC) around 20 million people are infected with HPV and additional 6.2 million people are newly infected every year. According to National Health and Nutrition Examination Survey in 2003-2004 among sexually active women (57% of 14 to 19 years and 97% of 20 to 59 years) HPV was highest prevalent in youngest age group (40% of 14-19 years and 50% of 20-24 years). Infection rates decrease after age of 24 years. There are more than 100 types of HPV viruses out of which 40 cause genital infections. Out of

As the Center for Disease Control (CDC) (2015) confirms, human papillomavirus (HPV) is the most common sexually transmitted infection (STD or STI) among men and women; it is so common that nearly every sexually active individual will get it at some point in their lives. With about 14 million new cases each year, the CDC (2015) reports a prevalence of about 79 million cases of persons currently infected with HPV in the United States (US). Also, with cervical cancer being the most serious outcome related to HPV, the state of Georgia falls in the mid-interval of 6.66 to 7.87 with HPV-related cervical cancer per 100,000 people. It is evident that this disease is more prevalent in rural areas and among underserved populations. HPV is actually

Among the many arguments for mandatory HPV vaccination, the foremost is that it is an important medical achievement and a major public health milestone. This vaccine has proven to be one-hundred percent effective in preventing the 4 HPV strains that are responsible for seventy percent of cervical cancers and ninety percent of genital warts. In addition, no serious side effects have been identified. Because this vaccine is a preventive measure, administration before onset of sexual activity is ideal; however, even females who have been sexually active can still benefit from this vaccination (Perkins et al., 2010). Nationally and internationally, the HPV vaccine will significantly reduce disease burden by reducing monetary and psychological costs of invasive procedures that remove precancerous and cancerous lesions. By combining vaccination with routine Pap smear screening, these public health efforts have the remarkable opportunity to eradicate cervical cancer (Ramet et al., 2011).

Human Papilloma Virus (HPV) remains the most commonly sexually transmitted infection in both males and females. (Giuliano et al., 1999).